|
|
|
|
|
|
by tomp
1692 days ago
|
|
|
Of course, and I'm not debating vaccine vs virus here (I've had both, myself), but even a single case of myocarditis (if we can conclusively prove that it comes from the vaccine... in reality, we can at most statistically suspect vaccine causes it) disproves the idea that "spike protein doesn't enter the bloodstream". |
|
|
Where I got my doubts about the "doesn't cross" claim, at least concerning Pfizer, which I researched :
- The identification of the spike, its in-vitro re-engineering, the formulation of a vaccine recepy took approximately two and a half months, from early Feb., 2020 to Apr. 27th, 2020. They started animal testing (60 mice, 12 monkeys) and on human volunteer (21) in parallel. It ended on Jul. 27th, '20.
- According to CT doc and FT docs, and publications, no study of biodistribution, on the theory that intra-musculary jab doesn't spread... Even though the spike protein was studied in the past (IIRC 'twas even patented around 2012 !), I didn't find any publication related to it saying it didn't cross such barriers, quite the contrary.
- They started the 40K volunteers CT right after, because of the reported absence of unwanted effects on the 20 first volunteers. Reportedly no change in formulation. Still no study.
- They started mass manufacturing during the second half of october, still no change in formulation, still no study.
The only indication of such a study was started was in the famed re-authorization letter a month ago, about them doing it now.
How and why is that even possible ? BionTech team is perfect on their first try at making a vaccine, as opposed a tailored gene therapy ? Really ?
Also :
- How do they prevent a cell presenting an anchored spike to clump with another cell with an ACE2
- Where is the study of the quality of that anchoring (i.e. what percentage of spikes don't anchor ?)